Companies
Serum Institute
Global vaccines — Massive-scale bioproduction.
- Country
- India
vaccines
in
legacy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | 4 billion doses annually (Pune facilities) | seruminstitute.com |
| Certification | cGMP compliant (WHO, USFDA, and European standards) | careratings.com · crisilratings.com |
| Regulatory approval | European Commission Marketing Authorisation (SIILTIBCY); WHO prequalification for various vaccines. | seruminstitute.com |
| Production site | Hadapsar (Pune, India) and Manjari (Pune, India); additional manufacturing plant in the Netherlands (Bilthoven Biologicals). | extranet.who.int · careratings.com · crisilratings.com |
| Revenue | ₹9,715 crore (approx. $1.16 billion USD) for FY2025 (Standalone operating income) | careratings.com · crisilratings.com |
Independent sources: careratings.com · crisilratings.com · extranet.who.int
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.